Athenex Inc (ATNX) EVP Rudolf Kwan Purchases 1,000 Shares

Athenex Inc (NASDAQ:ATNX) EVP Rudolf Kwan bought 1,000 shares of the firm’s stock in a transaction that occurred on Monday, November 19th. The shares were purchased at an average cost of $11.70 per share, with a total value of $11,700.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Rudolf Kwan also recently made the following trade(s):

  • On Wednesday, November 14th, Rudolf Kwan bought 10,000 shares of Athenex stock. The shares were purchased at an average cost of $10.49 per share, with a total value of $104,900.00.

NASDAQ:ATNX opened at $11.78 on Tuesday. Athenex Inc has a 52 week low of $9.83 and a 52 week high of $20.90. The company has a quick ratio of 3.86, a current ratio of 4.46 and a debt-to-equity ratio of 0.30.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings results on Wednesday, November 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.12. Athenex had a negative net margin of 143.42% and a negative return on equity of 71.94%. The business had revenue of $18.43 million for the quarter. On average, equities analysts forecast that Athenex Inc will post -1.65 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Legal & General Group Plc increased its stake in Athenex by 363.2% during the 2nd quarter. Legal & General Group Plc now owns 6,930 shares of the company’s stock valued at $129,000 after purchasing an additional 5,434 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in Athenex during the 3rd quarter valued at approximately $146,000. Man Group plc acquired a new position in Athenex during the 3rd quarter valued at approximately $201,000. Metropolitan Life Insurance Co. NY acquired a new position in Athenex during the 2nd quarter valued at approximately $266,000. Finally, Voya Investment Management LLC acquired a new position in Athenex during the 2nd quarter valued at approximately $294,000. Institutional investors and hedge funds own 20.93% of the company’s stock.

ATNX has been the subject of a number of analyst reports. LADENBURG THALM/SH SH initiated coverage on shares of Athenex in a research report on Thursday, October 25th. They set a “buy” rating and a $27.00 target price for the company. BidaskClub cut shares of Athenex from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 6th. JPMorgan Chase & Co. raised shares of Athenex from a “neutral” rating to an “overweight” rating and decreased their target price for the company from $24.00 to $15.00 in a research report on Thursday, November 15th. Zacks Investment Research cut shares of Athenex from a “hold” rating to a “sell” rating in a research report on Friday, August 17th. Finally, ValuEngine raised shares of Athenex from a “hold” rating to a “buy” rating in a research report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $22.00.

ILLEGAL ACTIVITY WARNING: “Athenex Inc (ATNX) EVP Rudolf Kwan Purchases 1,000 Shares” was published by WKRB News and is owned by of WKRB News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/20/athenex-inc-atnx-evp-rudolf-kwan-purchases-1000-shares.html.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Read More: Stock Selection – What is cash flow?

Insider Buying and Selling by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply